PF-07976016

PF-07976016 is an investigational small molecule drug developed by Pfizer for the treatment of obesity. It acts as a gastric inhibitory polypeptide receptor (GIPR) antagonist, targeting the glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory peptide) pathway. The drug is being evaluated in oral solution and oral suspension formulations. As of June 2025, it is in Phase IIa clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in adults with obesity[1][3][4][5][6][9]. Unlike some other agents in this therapeutic area that are GLP-1 receptor agonists or dual agonists (GLP-1/GIP), PF-07976016 specifically antagonizes GIPR[3][5]. The development of this agent follows Pfizer's discontinuation of other oral obesity candidates due to safety concerns[2][10].